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Sulnmal'y 
A novel Hodgkin cell line, designated HD-MyZ, was established from the pleural effusion of 
a 29-yr-old patient with Hodgkin's disease (HD) of nodular sclerosing type. The majority of 
cells grow adherently and display typical morphological characteristics of Reed-Steruberg  (RS) 
and Hodgkin (H) cells, i.e., large multi- and mononucleated cells with prominent nucleoli. 
Immunofluorescence analysis revealed  a myelomonocytoid immunophenotype (expression of CD13 
and CD68, and lack of lymphoid markers). HD-MyZ cells strongly expressed restin, a recently 
described intermediate filament-associated protein, the expression of which is restricted  to H 
cells, RS cells, and in vitro cultivated peripheral blood monocytes. In addition mRNA expression 
of c-f  ms (colony-stimulating factor 1 receptor) could be induced in HD-MyZ cells by phorbol 
myristate  acetate (PMA)  stimulation. Southern blot analysis did not detect rearrangement of 
T  cell  receptor  j8  and immunoglobulin H  loci,  thus  demonstrating the lack  of lymphoid 
commitment. HD-MyZ cells were also devoid of Epstein-Barr  virus genomes. HD-MyZ cells 
constitutively express mRNAs for interleukin lo~ (IL-lc~), IL-1/~, IL-5, IL-6, IL-7, IL-8, IL-10, 
IL-1 receptor (type I), and IL-6 receptor. Stimulation of cells with PMA increased  mRNA expression 
as well as the secretion of IL-I~/, IL-6, and IL-8, and induced the de novo expression of IL-8 
receptors. Xenotransplantation into severe  combined immunodeficient (SCID) mice by intravenous 
or subcutaneous  inoculation led to development  of disseminated tumors with infiltrative and 
destructive  growth. In addition lymphadenopathy,  pleural effusion, and infiltration  of spleen 
were observed. Morphological and immunological analysis of tumor cells revealed  the same features 
as HD-MyZ cells. This cell line might be an important tool for understanding the pathogenesis 
and biology of HD. In addition the SCID mice model might prove helpful in developing new 
therapeutic strategies. 
H 
odgkin's disease (HD) 1 is characterized by the presence 
of typical malignant cells (multinucleated Reed-Stern- 
berg [RS] and mononucleated Hodgkin [H] cells) amid a back- 
ground of reactive lymphocytes, plasma cells, histiocytes, neu- 
trophils, eosinophils, and stromal cells (1). The cell of origin 
of HD still remains controversial (2). The establishment  of 
several HD-derived cell lines recently (3) enabled  a more 
I Abbreviations used in  this paper: HD,  Hodgkin's  disease; RS,  Reed- 
Sternberg; RT, reverse transcription. 
detailed analysis of the cellular origin as well as the biology 
of these tumor cells. These efforts, however, have been ham- 
pered by the fact that H  or RS cells usually account only 
for a minority of cells within the cellular background in HD 
tissue. Most of the cell lines were derived from pleural effusions 
containing RS or H  cells. Various hematopoietic cells, in- 
cluding lymphocytes,  monocytes,  and interdigitating retic- 
ulum cells, have been speculated to be the normal counter- 
part of RS and H  cells (2, 4-10).  The majority of tumor 
cell lines, however, derived from HD that have been described 
so far were found to be related to lymphocytes  (2, 4-7). 
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tures of HD  might reflect  the unbalanced production of 
cytokines, e.g., B symptoms (night sweats, fever, weight loss), 
eosinophilia, acute phase reaction proteins, and thrombocy- 
toffs. Subsequently the expression  of various cytokines has 
been studied in HD-derived tumor cell lines (11). 
In this report we describe the morphologic, immunopheno- 
typic, molecular genetic, and functional characterization of 
a novel HD-derived cell line (HD-MyZ) consisting of typical 
KS and H cells, which display myelomonocytoid  characteris- 
tics. An in vivo model of HD could be established by xeno- 
transplantation of HD-MyZ cells into SCID mice. 
Materials and Methods 
Case History.  H and lLS cells  were isolated  from a pleural  effusion 
of a 29-yr-old patient  with HD refractory to multiple therapy 
regimen. In 1980 HD of nodular sclerosing type (stage Ilia) was 
diagnosed in patient MZ. Initial treatment consisted of combined 
chemo- and radiotherapy. The patient relapsed several times with 
disseminated  manifestations,  including abdominal, cervical, and ax- 
illary lymph nodes, right proximal humerus, and right iliac crest. 
In September 1991 tumor progression could be observed with evo- 
lution of pleural effusion, infiltration of psoas muscle, and mul- 
tifocal bone marrow infiltration despite intensive chemotherapy. 
In addition the patient complained of fevers unresponsive to anti- 
biotics and antifungal therapy. The patient's general condition de- 
teriorated rapidly and the patient died in November 1991. Due to 
the fact that a high number of H and lLS cells  could be seen within 
the smear cytology of the pleural fluid, this was the first patient 
with HD from whom we made an attempt to derive a cell line. 
Culture Conditions and Reagents.  Cell population of the pleural 
fluid consisted  predominantly  of large mono- and multinuclear  cells 
with morphological  features  of H and RS cells. After Ficoll-Hypaque 
separation cells were transferred into culture and maintained in 
I~PMI 1640 (Seromed-Biochrom,  Hamburg, Germany), 20% heat- 
inactivated  FCS, 2 mM L-glutamine  (Gibco, Karlsruhe, Germany), 
and penicillin-streptomycin  (Seromed-Biochrom).  Where indicated, 
cells were cultured in the presence of PMA (10 ng/ml; Sigma  Chem- 
ical Co.,  Miinchen, Germany) or LPS (Sigma Chemical Co.). 
Human PBL were cultured in RPMI plus 5% FCS in the presence 
of 5 ng/ml PMA plus 0.1% PHA for 24 h. Thereafter, cells were 
harvested for lLNA extraction. The Burkitt lymphoma cell lines 
BJAB, Raji, and BL60 and the T cell lymphoma call line Jurkat 
were used as controls in various experiments. 
Analysis of  Antigen Expression by Immunofluorescence.  Cells  were 
analyzed after staining with various mAbs. The antibodies were 
obtained from the panel of the Fourth International Workshop on 
Leucocyte  Differentiation  Antigens or purchased  from Becton Dick- 
inson & Co. (Heidelberg, Germany) and Coulter (Krefeld, Ger- 
many). TNF receptor mAbs utr-1 (type II receptor) and htr-9 (type 
I  receptor)  were kindly provided by Dr.  Manfred Brockhaus 
(Hoffmann-IaRoche, Basel, Switzerland). mAb anti-APO-1 (IgG3) 
was a generous gift from Dr. Peter Krammer (German Cancer Re- 
search Center, Heidelberg, Germany). Cells (106) were incubated 
with 5 ~tg/ml mAb in PBS (Containing 0.1% NaN3 and 10% 
human  IgG;  Venimmun Behring,  Marburg,  Germany). After 
washing, cells were incubated with Biotin (Fab)2 goat anti-mouse 
IgG (Dianova, Hamburg, Germany) for 30 rain at 4~  Thereafter 
cells were incubated with Streptavidin-FITC (Dianova), washed, 
and fixed  with 1% formalin. Indirect immunofluorescence  was mea- 
sured using a FACScan  |  flow cytometer (Becton Dickinson & Co.). 
Human tumor cells were detected in SCID mice by staining with 
an anti-human HLA-DIL mAb (B8.12.2; Dianova), which does 
not crossreact with mouse cells. Double staining of human tumor 
cells from SCID mice was performed using a PE-labeled anti-HLA- 
DR mAb (Dianova) and FITC-labeled CD13, CD19, CD71, and 
CD25 mAbs (Becton Dickinson & Co.). 
Cytoplasmic antigens were detected as described using cytocen- 
trifuge preparations (12). Cells were fixed with paraformaldehyde 
and treated with Triton X-100 (0.5%). After incubation with mAb, 
cells  were stained with  FITC-labeled  goat  anti-mouse  IgG 
(Dianova). 
Xenotransplantation of Tumor Cells into SCID Mice.  HD-MyZ 
cells (10  6  ) were injected either subcutaneously  or intravenously  into 
C.B.-17 scid/scid  mice (13). The mice were obtained from our own 
breeding colony and were kept in isolators under stringent condi- 
tions in the Central Animal Laboratory, German Cancer Research 
Center. Microbiological  controls were performed regularly by ad- 
dition of sterile sentinel animals to the colony. 
Detection of Cytokines by ELISA.  Secretion of Ibl/~, IL-6, and 
Ib8 into the supernatant of HD-MyZ was measured  by Quantikine 
assays (Biermann, Bad  Nauheim,  Germany) according to  the 
manufacturer's manual. 
Detection ofmRNA by PCR.  Total  RNA was extracted from 
viable calls as described by Gough (14). Purification of poly(A  +) 
RNA from 10/~g of total RNA was performed using the Dy- 
nabead mlLNA Purification Kit (Dynal, Oslo, Norway). Detec- 
tion of mlLNA by PCIL was performed as described by Wang et 
al. (15) using a Geneamp RNA PCR Kit (Perkin Elmer-Cetus, 
Ubedingen, Germany)  and a thermocyder (Bachhofer,  Reutlingen, 
Germany) according to the PCIL kit protocol. In detail, 1/~1 of 
the eluted poly(A  +) mlLNA (total volume, 20/~1) was used for 
reverse transcription (ILT) with a sequence-specific downstream 
primer directly followed  by a PCR amplification  step using an up- 
stream primer. To rule out false-positive  results due to DNA con- 
tamination, we always ran negative controls without RT. One- 
third of the PCIL volume was run on an agarose gd (1%). After 
transfer to a nylon membrane and UV crosslinking, filters were 
prehybridized  in hybridization  buffer (50%, vol/vol, formaldehyde, 
6￿  SSC, 0.1% SDS) for 4 h at 55~  cDNA was hybridized with 
a 32p-labeled internal oligonucleotide  complementary  to a sequence 
between the upstream and downstream primers. Probes were la- 
beled using a Y-oligonucleotide end-labding kit (British Biotech- 
nology, Oxford, UK). Filters were hybridized for 16 h at 55~ 
Filters were then washed twice for 30 rain with 6x  SSC, 0.1% 
SDS at 70~  Table 1 shows oligonucleotide sequences used for 
RT-PCR and hybridization as well as length of the expected PCP, 
products (16-47). 
Southern Blotting and Hybridization Probes.  Total  cellular DNA 
was extracted and digested with restriction endonucleases using 
standard protocols (48). 10/~g of digested DNA was electropho- 
retically separated  in 1% agarose  gels and transferred  to nylon mem- 
branes (Genescreen  Plus; DuPont Co., Wilmington, DE). Hybrid- 
ization probes labeled with 32p using the oligo-primed labeling 
method (49) were used in 50% formamide, 2x  SSC at 42~  (Tin, 
-20~  Control DNA was extracted from placenta, the human 
Burkitt lymphoma lines BJAB, Namalwa, and BL60, as well as 
the T lymphoma cell line Jurkat. 
To analyze  the human Ig heavy chain gene and the TCtL-~ gene 
for rearrangements, a genomic  2.2-kb Sau3a fragment of the joining 
region (IgHj region) (50) and an 800-bp cDNA sequence 0UIL- 
b2) (51) were used, respectively. For the detection of EBV DNA 
the Bgl2 U fragment (nucleotides 13944-17016) (52) specific for 
the EBV internal repeat 1 (IlL 1) was used. 
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mRNA  bp  5'-3' Sequence  3'-5' Sequence  Internal oligonucleotide 
/~-actin(16)  246  GAGCTGCGTGTGGCTCCCGAGG 
IL-1/~(17)  610  CCTCCAGGGACAGGATATGGAGC 
IL-2(18)  458  ATGTACAGGATGCAACTCCTGTCTT 
IL-2R(Tac)(19)  502  CCCTTGGCTCAATCCTCTAAG 
IL-3(20)  449  ATGAGCCGCCTGCCCGTCCTG 
IL-4(21)  408  CCTCCCAACTGCTTCCCCC 
IL-4R(22)  472  TCTTCCACCTTCGGGAAGTACG 
IL-5(23)  368  CCCCACAGAAATTCCCACAAG 
IL-6(24)  595  GGATTCAATGAGGAGACTTGCC 
IL-6R(p80)(25)  251  CATTGCCATTGTTCTGAGGTTC 
IL-7(26)  402  CATGGTCAAAACGGATTAGGG 
IL-7R(27)  605  GCCCTCGTGGAGGTAAAGTGCC 
IL-8(28)  308  GGACAAGAGCCAGGAAGAAACC 
IL-SR(29)  440  GGGGGACGCTATAGGATGTGGG 
IL-10(30)  467  CCCTGACCTCCCTCTAATTTATC 
GM-CSF(31)  424  ATGTGGCTGCAGAGCCTGCTGC 
TNF-c~(32)  450  GACAAGCCTGTACGGCATGTTG 
TNF-/~(33)  421  CCTCAAACCTGCTGCTCACCTC 
TNF-R.I(34)  601  GTGGAAGTCCAAGCTCTACTCC 
TNF-RII(35)  468  CTGCCGATAAGGCCCGGGGTAC 
c-rayc(36)  564  CCGCCCGCGGCCACAGCGTCTG 
c-myb(37)  610  GCCTCCTTTAACTTCCACCCCC 
c-fgr(38)  520  GGCGGTGAAGACGCTGAAGCCG 
N-ras(39)  464  CCCACCATAGAGGATTCTTAC 
bc1-1(40)  444  CGGGAAAGGCCACCTGTCCCAC 
bci-2(41)  441  GGTGCCACCTGTGGTCCACCTG 
p53(42)  576  GGCCCCTGTCATCTTCTGTCCC 
TGF-/~(43)  530  GCGCCCACTGCTCCTGTGACAGC 
restin(44)  420  GGCAGCTCAGCAGCTCCTCAGGT 
IL~1,v(17)  308  GTCTCTGAATCAGAAATCCTTCTATC 
IL-1R,  I(45)  548  GGTACAGGGATTCCTGCTATG 
c-kit(46)  452  CGGGAAGCCCTCATGTCTGAAC 
c-f  ms(47)  491  CCATGGATGGGGCGACACGGGG 
CGCAGGATGGCATGGGGGAGGGCATACCCC 
GGCTCAATAAAAGGGCTGGGG 
GTCAGTGTTGAGATGATGCTTTGAC 
CTGGGGAGCTGGGGTTATAGGC 
GCGAGGCTCAAAGTCGTCTGTTG 
GCCTTTCCAAGAAGTTTTTCC 
GGCCTGGGTGCCACCCTGCTCC 
GGCCTGACTCTTTCTTGGCCC 
CAAACTGCATAGCCACTTTCC 
AGTAGTCTGTATTGCTGATGTC 
CTCTCTTATTCTCACCGGC 
GGGAGACTGGGCCATACGATAG 
CTTCAAAAACTTCTCCACAAC 
CACAAGGCCAGTTGGCAGGTTG 
CAGGCTGGAGTACAGGGGCAC 
CTGGCTCCCAGCAGTCAAAGGG 
GGGCAATGATCCCAAAGTAGAC 
AGTTCTACAGAGCGAAGGCTCC 
CGATGTCCTCCAGGCAGCCCAG 
GCTTCATCCCAGCATCAGGCAC 
CCTCGGTGTCCGAGGACCTGGG 
CTGCTCCTCCATCTTTCCACAG 
GCCTGGGTAGGGGATTCGGCCC 
GGTAATCCCATACAACCCTGAG 
CATCCTGGCAATGTGAGAATGC 
GTTCACTTGTGGCCCAGATAGG 
GCCGGTCTCTCCCAGGACAGGC 
GGCGGGGCGGGGCGGGGCGGG 
AAGGTTTCGTCGTCATTGCAGTTGG 
CATGTCAAATTTCACTGCTTCATCC 
GGTGACCGTCGCTGGACTGGC 
GCGAGGAAAGCCATGCCCTTTG 
GGAGTGAAGGCGGCGTATAGGG 
GCCAGTGGTAGCGCCAGAGGCGTACAGGG 
GGAGAGAGCTGACTGTCCTGGCTGATGGAC 
CTTCTTCTAGACACTGAAGATGTTTCAGTTC 
CTCTTAAAGAGGCCAATTAGTAACGCACAG 
GCCTCCAGGTTTGGCCTTCGAAGGTTATTTTC 
CCGTTTCAGGAATCGGATCAGCTGCTTGTG 
GGACATTTCGGCGGAGGATCTGTCCCCAGG 
CCCCCTTGCACAGTTTGACTCTCCAGTGTG 
GTGTCCTAACGCTCATACTTTTAGTTCTCC 
CATCTGGTCGGTTGTGGCTC 
CTCTAAAACATCTCCAGCACAGAAGAAGAC 
GCTGATGGTTAGTAAGATAGGATCCATCTCC 
GTTCTTTAGCACTCCTTGGCAAAACTGCAC 
CACCTGAGATGGGAAAACCACCCCCCTGAG 
GTGCTGGGACTACAGGCGTGAGCCACCGCG 
GCTGGCCATCATGGTCAAGGGGCCCTTGAGC 
GGGCCGATTGATCTCAGCGCTGAGTCGGTC 
AGGGCTGAGGACTAGGTGGGGGATGCCATC 
GCTTGAAGGAACTACTACTAAGCCCCTGG 
GCTCCAGCAGCAGCTCCCTGGAGAGCTCG 
GCAGGATAGTCCTTCCGAGTGGAGGGAGGC 
CTGCTACAAGGCTGCAAGGGGCTCGCCAGG 
GAGCTCAGTGAGCAGGATCCCAAAGGACC 
CTTCAACACCCTGTCTGGTCTTGGCTGAGG 
GGCACGCAGCCTCCCAAACACCCCACCTCC 
AGGGCGTCAGGTGCAGCTGCCTGGACATC 
CCTCAAAGCTGTTCCGTCCCAGTAGATTAC 
GGGGCAGGGCCCGAGGCAGAAGTTGGCATG 
GGGCGTTCCTCACCCCGACTGCCATGGTG 
GATTGATGCATGGACCCTTGATGGAGTGGGCC 
CATGGCTATTTGCTCTTCAGATGAACCACC 
GGCCAACTCGTCATCCTCCATGATGGCGGG 
CCTGCTCCAAGGGGCCTGAGCTGAGTGTGG 
Results 
Cell Culture and Cytology.  Mono- and muhinuclear cells 
with characteristics of H and RS cells were isolated from the 
pleural fluid by Ficoll-Hypaque separation and were trans- 
ferred into culture medium as described. The majority of the 
cells grew adherently. Large muhinucleated RS-like cells (as 
shown in Fig. 1 a) account for •10%  of the cell population 
at a stable  frequency. Ceils were grown at a concentration 
of 10  ~ cells/ml,  and  culture  medium  was  replaced every 
other day. 
Ceils have been in continuous culture without morpho- 
logical and phenotypical changes since November 1991. Cyto- 
logic appearances of the cell line HD-MyZ demonstrating 
the typical morphological features of RS and H cells are shown 
in Fig. 1 a. Fig. 1, b and c, show hematoxyline/eosin staining 
of patient's bone marrow sections with infiltration by H and 
RS cells. 
HD-MyZ Cells Display Myelomonoq/toid  Features.  Pheno- 
typic analysis of the cell line was performed by immunofluores- 
cence using a flow cytometer and cytocentrifugation (Table 
2). RT-PCR was used for analysis of mRNA expression. Cells 
strongly expressed CD13 (MyT), MHC class II (HLA-DR), 
and CD68, but did not express either B or T cell lineage-as- 
sociated antigens, thus indicating myelomonocytoid differen- 
tiation. 
Cells were also positive for MHC class I, transfetfin receptor 
(CD71), CD10, and CD29 (integrin 81 chain). The activa- 
tion antigen CD30 (Ki-1), which is strongly expressed on 
1259  Bargou  et al. Figure  1.  Morphology of HD-MyZ cells: (a) 
Cytospin preparations. HD-MyZ cells (mono- and 
multinucleated  cells) were stained with hematox- 
ylin/eosin (x 63). (b and c) Bone marrow sections 
from patient MZ were stained with hematoxylin/ 
eosin. Infiltration of the patient's bone marrow by 
H  and RS cells (x 100). 
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B cell lineage  T  cell lineage  Myeloid lineage 
CD antigen  Expression  CD antigen  Expression  CD antigen  Expression 
Other 
CD antigen  Expression 
CDI9(HD37) 
CD20(IF5) 
CD21(HB5) 
CD37(HD28) 
CD22(HD39) 
CD23(HD50) 
CD38(T10) 
CD39(AC-2) 
CD40(G28-5) 
CD76(HD66) 
CD77(BLA-1) 
IgG 
IgD 
IgM 
CDla(T6) 
CD2(T11) 
CD3(Leu-4) 
CD4(Leu-3) 
CD7(Leu-9) 
CD8(Leu-2) 
CDS(Leu-10) 
B 
m 
CD13(My7)  + + + 
CD14(Mo2) 
CDltb(Mol) 
CDa3(My9) 
CD34(My10) 
CD15(L16) 
CD68(cytopl)  + + 
TNF-RI(utr-1) 
TNF-RII(htr-9) 
CD25(TAC) 
CD10(J5)  + + 
CD56(L19) 
CD71  + 
CD29(4B4)  + + + 
MHC II(HLA-DR)  + + + 
MHC I(W6/32)  + + 
CD30(Ki-1) 
APO-I/Fas 
HEA-125 
H  and RS cells in most cases of HD, could not be detected 
on the cell surface.  A  weak cytoplasmic staining,  however, 
was repeatedly observed. 
Recently, a novel intermediate filament-associated protein, 
designated restin, has been described, which is found to be 
expressed in in vitro cultured human peripheral blood mono- 
cytes. This novel marker appears  to be abundantly expressed 
in RS cells (44).  Using RT-PCR analysis  we were able to 
detect restin mRNA expression in HD-MyZ cells (Fig.  2). 
Germ Line Configuration  of the IgH and the TCR-~ Loci in 
HD-MyZ.  Since HD-MyZ cells were lacking cell surface 
markers of lymphoid differentiation but revealed instead my- 
elomonocytoid features (coexpression of CD13,  HLA-DR, 
CD68,  and restin), we were interested in further studying 
lymphoid commitment on a molecular genetic level. Using 
BamHI- or EcoRI-digested DNA from HD-MyZ cells no 
rearranged bands were detected with IgJ, region of TCR/$ 
probes  (Fig.  3). 
Absence of  EBV Genomes in HD-MyZ.  No EBV-specific 
sequences were detected in HD-MyZ (H) as well as the EBV- 
negative cell lines BJAB (B)  and Jurkat  (J).  In the human 
Burkitt's  lymphoma line Namalwa(N),  which carries two 
integrated copies of the EBV genome (51), the 3.1-kb BamHI 
fragment (W)  is clearly detected (Fig.  4). 
mRNA  Expression of Oncogenes, Cytokines, and Cytokine 
Receptors.  We studied the mRNA expression of a number 
of well-characterized proto-oncogenes and suppressor genes. 
As shown in Fig.  5 a, specific transcripts of p53, c-myc, and 
bob1 could be detected. In addition expression of N-ras and 
c-myb was also detected, whereas mRNA expression of bcl-2 
and c-fgr  oncogenes was not observed. Expression of the proto- 
oncogene c-f  ms (CSF-1 receptor) could be observed after PMA 
stimulation for 8 h (Fig. 6 b). Table 3 summarizes the expres- 
sion of these genes in HD-MyZ cells. 
Since part of the clinical  symptoms and of the pathology 
of HD might be explained by the unbalanced production of 
tumor cell-derived cytokines, we were interested in studying 
the constitutive mRNA expression of cytokines and their 
receptors.  HD-MyZ cells were found to constitutively ex- 
press transcripts of IL-lc~, IL-1/$, IL-5, IL-6, IL-7, IL-8, IL- 
10, as well as IL-1 (type 1) receptors (Fig.  5 b). In contrast, 
the cells did not express TNF-~ IL-3, or GM-CSF (Fig. 5 c). 
Table  3  summarizes  the  data  on  cytokines  and  cytokine 
receptors. 
In  addition,  we studied the regulation of cytokine and 
cytokine receptor expression after in vitro stimulation with 
phorbol esters.  In vitro stimulation with PMA for 24 h in- 
duced the de novo expression of IL-SR mRNA (Fig.  6 a). 
Secretion of Cytokines.  We assessed  the secretion of IL- 
I/$,  IL-6, and IL-8 into the cell-free supernatant of our cell 
line by ELISA.  In accordance with our mRNA expression 
data, high levels of IL-8 and moderate levels of IL-6 and IL- 
1/$ could be detected in the supernatant of unstimulated HD- 
MyZ cells. Stimulation with PMA for 40 h led to a marked 
increase in  IL-6,  IL-8,  and IL-13  secretion (Table 4). 
Xenotransplantation into SCID  Mice.  106  cells  were  in- 
Figure 2.  Restin  expression  in HD-MyZ. Au- 
toradiographs  of  blotted and hybridized  RT-PCR 
products. Constitutive restin mRNA expression 
is observed  in HD-MyZ cells (lane 1), whereas 
freshly  isolated  human  PBL did not express  restin 
mRNA (lane  2). B-actin expression  in both cell 
lines was used as control. 
1261  Bargou  et al. Figure  4.  Absence  of  EBV  ge- 
nomes in HD-MyZ. A Southern blot 
of BamHI-digested DNA was pre- 
pared as described in Fig. 3 and was 
hybridized with a probe specific for 
the EBV internal repeat 1 (EBV IR1). 
No EBV-specific sequences were de- 
tected in HD-MyZ (/-/) as well as the 
EBV-negative cell lines BJAB (B) and 
Jurkat  0).  In  the  human  Burkitt's 
lymphoma line Namalwa (N), which 
carries two integrated copies of the 
EBV genome (53), the 3.1-kb BamHl 
W  fragment (W) is clearly detected. 
Figure  3.  Germline configuration of the IgH and the TCR-B loci in 
HD-MyZ. Approximately 10/~g of cellular DNA was digested with BamHI 
and EcoRl restriction endonucleases, respectively, separated by electropho- 
resis in 1% agarose gds, transferred on nylon membranes,  and hybridized 
with a 32P-labeled  IgH J region-specific DNA probe and autoradiographed 
(top). After removal of the IgH J probe the same blot was rehybridized 
with a cDNA probe specific for the TCR fl gene (bottom). The IgH ] 
region probe detected germ line fragments of 16 kb (BamHI) and 13 kb 
(EcoRI) in HD-MyZ (/4) as well as in human placenta DNA (P) and the 
human T  cell line Jurkat (I). In control DNA from B lymphoma lines 
BJAB (B)-, Namalwa (N)-, and BL60  (B/), rearranged fragments were 
present.  The TCIk B gene probe detected germ line fragments of'~20 kb 
(BamHl) and 11, 4, and 3.5  kb (EcoR1) in HD-MyZ (H) as well as in 
all control call lines, except for the T cell line Jurkat (/'), which contains 
an additional rearranged 9-kb EcoRI fragment. 
jected either intravenously  or subcutaneously into SCID mice. 
Animals from both groups developed fatal disease  within 5 
wk after injection. At autopsy massive tumors were observed 
at  the  site of injection (subcutaneous  group).  In  addition, 
infiltration and enlargement of axillary,  inguinal,  and retro- 
peritoneal lymph nodes and spleen as well as pleural effusion 
were noticed. In contrast to subcutaneous application, intra- 
venous injection led to a more prominent infiltration of the 
visceral organs, a massive  pleural effusion, and psoas muscle 
infiltration. Primary tumor tissue consisted of large KS- and 
H-like cells. The spleen was found to be infiltrated by tumor 
cells  (Fig.  7,  a  and  b). 
For detection of human cells within single call suspensions 
of tumor cells obtained from the primary tumor (subcuta- 
neous  group),  metastatic lymph nodes,  spleen,  and  pleura1 
effusion by flow cytometry (FCM) analysis, a PE-labeled anti- 
human HLA-DR antibody was used that does not crossreact 
with mouse calls.  HLA-DR + cells were gated.  FCM anal- 
ysis  of these  SCID  mice-derived  tumor cells  with  double 
immunofluorescence was performed using PE-labeled  anti- 
human HLA-DR  and FITC-labded  CD13,  CD19,  CD25, 
Figure  5.  mKNA expression of cytokines, cytokine receptors, and proto-oncogenes in HD-MyZ cells. (a) RT-PCR products were blotted, autoradio- 
graphed, and hybridized as described above. Specific transcripts for c-myc, p53, and kl-1 were detected in unstiraulated I--ID-MyZ  cells. (b and c) Autora- 
diographs of blotted and hybridized KT-PCK products are depicted. (b) Specific transcripts for IL-lfl, IL-1 receptor(type 1), IL-5, IL-6, Ib7, and IL.8 
were observed, whereas mRNA products of TNF-c~, IL-3, and GM-CSF could not be detected in HD-MyZ cells (lanes 1, 3, and 5). Raji cells (lanes 
2 and 6), PHA plus PMA-stimulated human PBL  (lane 4),  as well as B-actin ~pression were used as controls (c). 
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1 receptor)  is induced in HD-MyZ  by PMA treatment. (a) HD-MyZ  calls 
were in vitro activated with 10 ng/ml PMA for 24 h (lane 2). Control 
cells were cultured for the same period in culture medium alone (hne 1). 
In control calls no IL-8 receptor mRNA expression  could be detected. In 
contrast, significant amounts of IL-8 receptor  transcripts were observable 
after 24 h of PMA stimulation, fl-actin expression served as control. (b) 
HD-MyZ cells were stimulated with 10 ng/ml PMA. Unstimulated cells 
did not reveal c-f  ms expression (lane I), whereas c-fins transcripts could 
be detected after 8 h of PMA stimulation. 
and CD71, and revealed  a phenotype corresponding  to that 
of HD-MyZ cells  (Fig.  8).  Cells from all these tumor sites 
were transferred into culture medium and showed the same 
growth  characteristics. 
Discussion 
The pathogenesis of lid and, at its center, the cdlular origin 
of the H  or P,S cells  still remain  enigmatic.  Almost every 
hematopoietic  cell,  including  both  B  and  T  lymphocytes, 
monocytes/macrophages,  myeloid cells,  and interdigitating 
reticulum cells,  has been speculated to be the normal coun- 
terpart (for review see reference 2). With the advent of sev- 
eral HD-derived tumor cell lines it has been possible to carry 
out detailed studies on the biology and the origin of these 
cells.  Due to the fact that  H  or RS cells account  only for 
a minority of cells within  the bystander cells in HD tissue 
and that many attempts to cultivate H  or RS cells failed,  one 
has to bear in mind that those cell lines,  which were success- 
fully derived from HD, might  only reflect a certain  aspect 
of the disease.  Thus, one has to be careful in drawing gener- 
alizations from these cell lines about the in vivo biology and 
origin  of H  or RS calls. 
We describe the successful establishment of a novel H  cell 
line,  which was derived from the pleural fluid of a patient 
with HD of nodular sderosing type. The morphological anal- 
ysis of the cells within the pleural effusion disclosed the typ- 
ical features of RS and H cells, i.e., large multinucleated and 
mononucleated cells with prominent nudeoli. These cells were 
transferred into culture medium,  grew adherently,  and have 
been in continuous culture since November 1991.  The im- 
munophenotyping disclosed that the HD-MyZ cell line was 
devoid of B or T  lineage-associated markers (Table 2). HD- 
MyZ cells were found to strongly express CD13, a cell sur- 
face antigen expressed on myelomonocytic cells. MHC HLA- 
DR, CD71, CD10, and cytoplasmic CD68 were also detected. 
This phenotype (CD13 +, CD68 + , HLA-DR +) is compat- 
ible with myelomonocytic differentiation (54, 55). Repeated 
FCM analysis  did not  show any change  in cell surface an- 
tigen expression. CD13 (identical to aminopeptidase-N) and 
Table  3.  Constitutive  raRNA  Expression  of Selected  Cytokines, 
Cytokine  Receptors,  and Proto-oncogenes 
mRNA expression  HD-MyZ 
IL-la  + 
IL-1B  + 
IL-2 
IL-3 
IL-4 
IL-5  + 
IL  -6  + 
IL-7  + 
IL-8  + 
IL-10  + 
GM-CSF 
TGF-fl 
TNF-a 
TNF-3 
IL-1R(type 1)  + 
IL-2R(CD25) 
IL-3R(c~-chain) 
IL-4R 
IL-6R (p80)  + 
IL-7R 
IL-8R"  + 
TNF-R (type I) 
TNF-R(type II) 
c-m  F  + 
c-myb  + 
bcl-1  + 
bd-2 
c-k/t 
N-ras  + 
p53  + 
c-f~t" 
c-f  ms *  + 
* Induction after PMA stimulation. 
CD10  (identical  to neutral  endopeptidase)  are both metal- 
loproteases. Both proteases are thought to be involved in the 
inactivation  of regulatory peptides at the cell surface (56). 
CD30 expression was not observed on the cell surface of 
HD-MyZ cells.  Interestingly,  another HD-derived cell line 
(SU/KH-HD-1)  displaying  myelomonocytic features,  i.e., 
CD14 expression, was also described to be devoid of the HD- 
associated activation  antigen  CD30  (3). 
Analysis of IgH and TCR fl locus confirmed our assump- 
tion that HD-MyZ cells lack lymphoid commitment.  To our 
knowledge HD-MyZ is the only HD-derived cell line that 
is devoid oflg or TCR rearrangement.  Little is known about 
1263  Bargou  et al. Table  4.  Secretion  of Cytokines by HD-MyZ 
lhM  lhPMA  40hM  40hPMA 
pg/ml 
IL-I~  8  13  15  40 
IL-6  45  70  150  670 
IL-8  350  400  2,800  5,950 
106 cells/ml were incubated with culture medium in the presence or ab- 
sence of 10 ng/ml PMA. After the indicated incubation  period, cells were 
pelleted, cell-free supernatants  were collected, and cytokine concentra- 
tion was measured by ELISA. 
the involvement of specific oncogenes in the pathogenesis of 
HD. Studies on oncogene expression in different HD-derived 
cell lines revealed  a heterogeneous pattern. Frequently expressed 
proto-oncogenes were c-myc,  c-myb,  c-raf,  and N-ras  (57). 
In our cell line specific transcripts for c-myc,  c-myb,  bcl-1, 
N-ras,  and p53 tumor suppressor gene were detected. 
Since HD-MyZ cells showed phenotypical characteristics 
of myelomonocytoid differentiation (CD13,  CD68,  MHC 
class II), we were interested in studying the expression  of 
a recently described intermediate filament-associated protein 
designated restin (44), which is found to be expressed at high 
levels in H  and KS cells and in in vitro cultivated human 
peripheral blood monocytes. Specific restin transcripts were 
detected in HD-MyZ cells. Expression of the c-f  ms proto- 
Figure 7.  Infiltration of spleen and 
metastatic lymph node by tumor cells. 
Tumors  were  dissected from  SCID 
mice.  Hematoxylin/eosin-stained  sec- 
tions  from  metastatic  lymph  node 
tumor are shown (a), The tumor con- 
sists  of  large  anaplastic  multi-  and 
mononucleated cells resembling KS or 
H cells. (b) Hematoxylin/eosin-stained 
spleen sections demonstrating infiltra- 
tion by tumor cells. 
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Figure 8.  FCM  |  analysis  of  SCID mice  de- 
rived human tumor cells. 10  6 tumor cells were 
used for FCM analysis  with double immuno- 
fluorescence  using PE-conjugated  anti-HLA- 
DR mAb and FITC-labeled CD13 mAb or 
FITC-labeled  IgG1 control  mAb. For detection 
of human cells HLA-DR-positive  cells were 
gated. Contour plots are depicted. Coexpres- 
sion of CD13 and HLA-DR is observed  in all 
tumor calls. 
oncogene (CSF-1 receptor) could be induced in HD-MyZ 
cells by stimulation with PMA. c-f  ms expression is correlated 
with monocytic differentiation (58). 
HD is clinically characterized by B symptoms, elevated acute 
phase reaction proteins, thrombocytosis, and histopathologo 
ically by sclerosis, eosinophilia, plasmocytosis, lymphocytic, 
and neutrophil reaction. These features might reflect the effects 
of tumor cell-derived cytokines. We therefore studied mRNA 
expression of various cytokines and cytokine receptors as well 
as the release of these cytokines into the supernatants. The 
pattern of cytokine production observed in HD-MyZ cells 
fits into the setting of monocytoid differentiation of this cell 
line and could explain some of the clinical and histopatho- 
logical features of HD. Autocrine production of growth factors 
has been suggested to be involved in the pathogenesis of var- 
ious hematologic malignancies. Thus, TNF-o~ has been pro- 
posed as autocrine growth factor in hairy cell leukemia (59), 
IL-I~ in acute myeloid leukemia (60), and IL-6 in plasmocy- 
toma (61). Since some cytokines (IL-lo~,  IL-1B, IL-6) were 
expressed constitutively in conjunction with their receptors, 
an autocrine growth model might also exist in HD-MyZ cells. 
Recently IL-6 secretion as well as IL-6 receptor expression 
were observed in several H  cell lines (HDLM-2,  KM-H2) 
as well as in HD tissue (62,  11). Neutralizing antibodies to 
recombinant IL-6, however, did not inhibit the growth of 
the cell lines tested (11). 
Using immunoperoxidase staining of tumor tissue,  IL-1 
expression was observed in 20 patients with HD and in pa- 
tients with true histiocytic malignancies, whereas B or T cell 
lymphomas were devoid of IL-1 expression (63). The authors 
argued that this observation might provide further evidence 
for the relationship between RS cells and interdigitating retic- 
ulum cells.  In the mean time IL-1 expression has been de- 
scribed in a variety of tumors. IL-1 has been discussed as an 
autocrine growth factor in acute myeloblastic leukemia (see 
above). Since HD-MyZ cells display monocytic features and 
simultaneously express IL-lcr  IL-13, and IL-1 receptors, IL-1 
appears to be a likely candidate for an autocrine growth factor. 
Further studies using neutralizing antibodies or antisense oli- 
gonucleotides are warranted to clarify this model. 
Due to the fact that HD-MyZ constitutively secretes large 
amounts of IL-8 in the absence of IL-8 receptors (which, how- 
ever, can be induced by PMA treatment), IL-8 might have 
an important  role as a paracrine rather than an autocrine 
cytokine. IL-8 might be responsible for inflammatory symp- 
toms in patients with HD. 
One important criterion for defining an in vitro growing 
cell as malignant is the tumorigenic growth in nude or SCID 
mice. In addition SCID mice provide a useful in vivo model 
for studying human lymphoma growth and in vivo therapy 
strategies (64).  The subcutaneous and intravenous inocula- 
tion of HD-MyZ cells into SCID mice led to the develop- 
ment  of large tumor masses  with  infiltrative,  destructive 
growth and to the evolution of extensive lymphadenopathy 
and splenomegaly. Histologically RS and H  cells could be 
detected in these tissues.  FCM analysis  of human cells de- 
rived from these SCID mice tumors revealed the same pheno- 
type as the parental in vitro cell line. 
Due to the fact that the patient-derived cell line led to the 
development of disseminated tumors in SCID mice mimicking 
the patient's clinical picture concerning the localization of 
disease manifestations, we have reason to assume that this 
cell line indeed represents the disease-causing tumor cell. Taken 
together our data might suggest the following pathogenet- 
ical model: an activated myelomonocytic  tumor cell with mor- 
phological characteristics of H  or RS cells furnished with 
a broad repertoire of cytokines might cause the tissue reac- 
tion, as well as the biological heterogeneity observed in HD, 
and might sustain its growth in an autocrine fashion. The 
model using SCID mice might be of great value for under- 
standing the biological heterogeneity of HD and for testing 
novel therapeutic interventions in vivo. 
We thank Ms. Barbara Maier for excellent technical assistance, and Drs. Antonio Pezzutto and Rudolf 
Leube for critical reading of the manuscript. 
1265  Bargou  et al. Address correspondence to Bernd Dtrken, Free University of Berlin, Universit~tsklinikum Rudolf Vir- 
chow, Robert-Rtssle-Klinik,  Lindenbergerweg 80, O-1115 Berlin-Buch, Germany. 
Received for publication  30 November  1992 and in  revised form  1 February 1993. 
References 
1.  Kaufman, D., and D.L. Longo. 1992. Hodgkin's Disease. Crit. 
Rev. Oncol./Hematol.  13:135. 
2.  Diehl, V., C. yon Kalle, C. Fonatsch, H. Tesch, M. Juecker, 
and M. Schaadt. 1990. The cell of  origin in Hodgkin's disease. 
Semin.  Oncol. 17:660. 
3.  Diehl, V., M. Pfreundschuh, C. Fonatsch, H. Stein, M. Falk, 
H. Burrichter, and M. Schaadt. 1985. Phenotypic and geno- 
typic analysis of  Hodgkiffs disease  derived  cell lines: histopatho- 
logical and clinical implications. Cancer Sum.  4:399. 
4.  Kanzaki, T., I. Kubonishi, T. Eguchi, S. Yano, H. Sonobe, 
K. Ohyashiki, K. Toyama, Y. Ohtsuki, and I. Miyoshi. 1992. 
Establishment of a new Hodgkin's cell line (HD-70) of B-cell 
origin.  Cancer (Phila.). 69:1034. 
5.  Drexler, H., D.B. Jones, V. Diehl,  and J. Minowada. 1989. 
Is the Hodgkin cell a T or B lymphocyte? Recent evidence 
from a geno- and immunophenotypic analysis and in vitro cell 
lines. Hematol.  Oncol. 7:95. 
6.  Agnarsson, B.J., and M.  Kadin. 1989. The Immunopheno- 
type of Reed-Sternberg cells: a study of 50 cases of Hodgkin's 
disease using fixed frozen tissues. Cancer (Phita,). 63:2083. 
7.  Falk, M.H., H. Tesch, H. Stein, V. Diehl,  D.B. Jones, C. 
Fonatsch, and G.W. Bornkamm. 1987. Phenotype versus im- 
munoglobulin  and T-cell receptor genotype of Hodgkin de- 
rived cell lines: activation  of immature lymphoid  cells in 
Hodgkin's disease. Int. J.  Cancer. 40:262. 
8.  Maksem, J.A., M.O. Hassan, and J.R. Carter. 1983. The ul- 
trastructural heterogeneity of the Reed-Sternberg cell and its 
resemblance to monocyte-macrophage differentiation in vivo. 
Ultrastruct. Pathol. 4:379. 
9.  Olson, L., and O. Behnke. 1985. Phenotypic attributes of the 
malignant cell population in Hodgkin's disease indicate a mono- 
cytic/macrophage origin.  Cancer Sum.  4:421. 
10.  Kadin, M.E. 1982. Possible origin of the Reed-Steinberg cell 
from interdigitating reticulum cell. Cancer Treat. Retx 66:601. 
11.  Gruss, H.J., M.A. Brach, H.G. Drexler, K. Bonifer,  K.H. Mer- 
telsmann,  and F.  Herrmann.  1992. Expression of cytokine 
genes, cytokine receptor genes and transcription factors in cul- 
tured Hodgkin and Reed-Sternberg cells. Cancer Res. 52:3353. 
12.  Dtrken, B., G. Moldenhaner, A. Pezzutto, R. Schwartz, A. 
Feller, S.  Kiesel, and L.M.  Nadler.  1986. HD 39(B3), a B 
lineage-restricted  antigen whose cell surface  expression  is limited 
to resting and activated human B lymphocytes. J. Immunol. 
136:4470. 
13.  Bosma, G.C., R.P. Custer, and M.J. Bosma. 1983. A severe 
combined immunodeficiency mutation in the mouse. Nature 
(Lond.). 301:527. 
14.  Gough, N.M.  1988. Rapid and quantitative  preparation of 
cytoplasmatic RNA from small numbers of cells. Anal. Bio- 
chem. 173:93. 
15.  Wang, A.M., M.V. Doyle, and D.F. Mark.  1989. Quantita- 
tion of mRNA by the polymerase chain reaction. Proc. Natl. 
Acad. Sci. USA.  86:9717. 
16.  Ponte, P., S.Y. Ng, J. Engel, P. Guning, and L. Kedes. 1984. 
Evolutionary conservation in the untranslated regions of actin 
mRNA's: DNA sequence of a human/~-actin cDNA. Nucleic 
Acids Res. 12:1687. 
17.  Nishida, T, N. Nishino,  M.  Takano, K. Kawai, K. Bando, 
Y. Masui, S. Nakai, and Y. Hirai. 1987. cDNA cloning oflblot 
and IL-1/~ from mRNA of U937 cell line. Biochem. Biophys. 
Res. Commun.  143:345. 
18.  Taniguchi, T., H. Matzui, T. Fujita, C. Takaoka, N. Kashima, 
R. Yoshimoto, and J. Hamuro.  1983. Structure and expres- 
sion of a cloned cDNA for human interleukin 2. Nature (Lond.). 
302:305. 
19.  Leonard, W.J., J.M. Depper, G.R. Crabtree, S. Rudikoff, J. 
Pumphrey, R.J.  Kobb, M. Krtnke, P.R Svetlik, N.J.  Peffer, 
T.A. Waldmann, and W.C. Greene. 1984. Molecular cloning 
and expression  of  cDNAs for the human interleukin-2 receptor. 
Nature (Lond.). 311:626. 
20.  Yang, Y.C., A.B. Ciarletta, P.A. Temple, M.P. Chung, S. Ko- 
wade., J.S. Witek-Gianotti, A.C. Leafy,  R. Kriz, R.E. Donahue, 
G.G. Wong, and S.C. Clark. 1986. Human II-3 (multi-CSF): 
identification by expression cloning of a novel hematopoietic 
growth factor related to murine  II.-3. Cell. 47:3. 
21.  Yokota, T.,  T.  Otsuko,  T.  Mosmann,  J.  Banchereau,  T. 
Defrance, D. Blanchard, J.E. De Vries, F. Lee, and Ki. Arai. 
1986. Isolation and characterization of a human interleukin 
cDNA clone, homologous to mouse B cell stimulatory factor 
I, that expresses  B cell- and T cell-stimulating activities. Prac. 
Natl. Acad. Sci. USA.  83:5894. 
22.  Idzerda, R.L., C.J. March, B. Mosley, S.D. Lyman, T.V. Boss, 
S.D. Gimpe, W.S. Din, K.H. Grabstein, M.B. Widmer, L.S. 
Park, D. Cosman, and M.P. Beckmann. 1990. Human inter- 
leukin 4 receptor confers biological responsiveness  and defines 
a novel receptor superfamily.  J. ExI~ Med.  181:861. 
23.  Azuma, C., T. Tanabae, M. Konishi, T. Kinashi, T. Noma, 
F. Matsuda, Y. Yaoita, K. Takatsu, L. Hammarstroem, C.I.E. 
Smith, E. Severinson, and T. Honjo. 1986. Cloning ofcDNA 
for human T cell replacing factor (interleukin 5) and compar- 
ison with the murine homologue. Nude/c Acids Res. 14:9149. 
24.  Wong, G., J. Witek-Giannotti,  K. Hewick, S. Clark, and M. 
Ogawa. 1988. Interleukin 6: identification as a hematopoietic 
colony stimulating  factor. Behring Inst. Mitt.  83:40. 
25.  Yamasaki, K., T. Taga, Y. Hirata, H. Yawata, Y. Kawanishi, 
B. Seed, T. Taniguchi, T. Hirano,  and T. Kishimoto.  1988. 
Cloning and expression  of  the human interleukin 6(BSF-2/IFN- 
B2) receptor. Science (Wash. DC).  241:825. 
26.  Goodwin, R.G., S. Lupton, A. Schmierer, K.J. Hjerrild,  R. 
Jerzy, W. Clevenger, S. Gillis, D. Cosman, and A.E. Namen. 
1989. Human interleukin  7: molecular cloning and growth 
factor activity on human and murine B lineage cells. Pro~ Natl. 
Acad. Sci. USA.  86:302. 
27.  Goodwin, R.G., D. Friend, S.F. Ziegler, K. Jerzy, B.A. Falk, 
S. Gimpel, D. Cosman, S.K. Dower, C.J. March, A.E. Namen, 
and  L.S. Park. 1990. Cloning  of the human  and  murine 
interleukin-7 receptors: demonstration  of a soluble form and 
homology to new receptor superfamily. Cell. 60:941. 
28.  Mukaida, N., M. Shiroo, and K. Matsushima. 1989. Genomic 
structure  of  the  human  monocyte  derived  neutrophil 
chemotactic factor I1.-8. J. Immunol.  143:1366. 
1266  A Novel Hodgkin Cell Line Mimicking Hodgkin's Disease in SCID Mice 29.  Holmes, W.E.,J. Lee, W.J. Kuang, G.C. Rice, and W.I. Wood. 
1991. Structure and functional expression of the human inter- 
leukin 8 receptor. Science (Wash. DC).  253:1278. 
30.  Vieira, P., R. deWaal-Malefyt,  M.N. Dang, K.E. Johnson, R. 
Kastelein, D.F. Fjorentino,  J.E. DeVries, M.G. Roncarolo, T.R. 
Mosman, and K.W. Moore. 1991. Isolation and expression of 
human cytokine synthesis inhibitory factor cDNA clones: ho- 
mology to Epstein-Barr  virus open reading frame  BZRF-1.  Proa 
Natl,  Acad. $ci. USA.  88:1172. 
31.  Wong, G.G., J.S. Witek, P.A. Temple, K.M. Wilkens, A.C. 
Leafy,  D.P. Lu~nberg, S.S. Jones, E.L. Brown, R.M. Kay,  E.C. 
Orr,  C. Shoemaker, D.W. Golde, R.J. Kaufinan, R.M. He- 
wick, E.A. Wang, and S.C. Clark. 1985. Human GM-CSF: 
molecular  cloning of  the complementary  DNA and purification 
of the natural and recombinant proteins. Science (Wash. DC). 
228:810. 
32.  Pennica, D., G.E. Nedwin, J.S. Ha)flick, P.H. Seeburg, R. 
Derynck, M.A. Palladino,  W.J. Kohr, 13.13. Aggarwal, and D.V. 
Goeddel. 1984. Human tumor necrosis factor: precursor struc- 
ture, expression and homology to lymphotoxin. Nature (Lond.). 
312:724. 
33.  Gray,  P.W., I3.13. Aggarwal, C.V. Benton, T.S. Bringman, W.J. 
Henzel, J.A. Jarrett,  D.W. Leung, B. Moffat, P.  Ng,  L.P. 
Svedersky, M.A. Palladino, and G.E. Nedwin. 1984. Cloning 
and expression ofcDNA for human lymphotoxin, a lymphokine 
with tumor necrosis factor activity. Nature (Lond.). 312:721. 
34.  H. Loetscher,  Y. Pan, H. Lahm, R. Gentz, M. Brockhaus, H. 
Tabuchi, and W. Lesslaner. 1990. Molecular cloning and ex- 
pression of the human 55kd tumor necrosis factor receptor. 
Cell. 61:351. 
35.  Smith, C.A., T. Davis, D. Anderson, L. Solam, M.P. Beck- 
mann, R. Jerzy, S.K. Dower, D. Cosman, and G.R. Goodwin. 
1990. A receptor for tumor necrosis factor defines an unusual 
family  of  cellular  and viral  protein. Science (Wash. DC). 248:1019. 
36.  Watt, R., L.W. Stanton, K.B. Marcu, R.C. Gallo, C.M. Croce, 
and G. Rovera. 1983. Nucleotide sequence of cloned cDNA 
of human c-myc oncogene. Nature (Lond.). 303:725. 
37.  Majello, B., L.C. Kenyon, and R. DaUa-pavera. 1986. Human 
c-myb protooncogene: nudeotide sequence of cDNA and or- 
ganization of the genomic locus. Proc. Natl. Acad. Sci. USA. 
83:9636. 
38.  Katamine, S., V. Notario, C.D. Rao, T. Miki, M.S.C. Cheah, 
S.R. Tronick, and K.C. Robbins. 1988. Primary structure of 
the human fgr proto-oncogene product p55-c-fgr. Mol. Cell. 
Biol. 8:259. 
39.  Hall, A., and R. Brown. 1985. Human N-ras: cDNA cloning 
and gene structure. Nucleic Acids Res.  13:5255. 
40.  Withers, D.A., R.C. Harvey,  J.B. Faust, O. Melnyk, K. Carey, 
and T.C. Meeker. 1991. Characterization  of  candidate  bcl-1 gene. 
Mol. Cell. Biol. 11:4846. 
41.  Cleary,  M.L., S.D. Smith, andJ. Skim. 1986. Cloning and struc- 
tural analysis  of  cDNAs for bcl-2 and a hybrid bcl-2/immuno- 
globulin transcript resulting from the t(14;18) translocation. 
Cell. 47:19. 
42.  Zakut-Houri, R.., B. Biemz-Tadmor,  D. Givol, and M. Oren. 
1985. Human p53 cellular  tumor antigen: cDNA sequence  and 
expression in COS ceils. EMBO (Fur. Mol. BioL Organ.)J. 4:1251. 
43. Derynck, R., J.A. Jarrett, E.V. Chen, D.H. Eaton, J.R. Bell, 
R.K. Assoian, A.B. Roberts, M.B. Sporn, and D.V. Goeddd. 
1985. Human transforming growth factor ~ complementary 
DNA sequence  and expression  in normal and transformed  cells. 
Nature (Lond.). 316:710. 
44.  Bilbe, G., J. Delabie,  J. BrOggen, H. Richener, F.A,M. Assel- 
bergs, N. Cerletti, C. Sorg, K. Odnik, L. Tarcsay,  W. Wiesen- 
danger, C. DeWolf-Pecters, and R. Shipman. 1992. Restin: a 
novel intermediate filament associated  protein highly expressed 
in the Reed-Sternberg  cells of Hodgkin's disease. EMBO (Fur. 
Mol. Biol. Organ.) J.  11:2103. 
45.  Chua, A.O., and U. Gubler. 1989. Sequence  of the cDNA for 
the human fibrobhst-type interleukin-1 receptor. Nucleic Acids 
Res. 17:10114. 
46.  Yarden,  Y.,  V.  Kuang,  T.  Yang-Feng, L.  Coussens,  S. 
Munemitsu, T.J. Dull, E. Chen, J. Schlessinger, U. Francke, 
and A. Ullrich. 1987. Human proto-oncogene c-kit: a new 
cell surface  receptor tyrosine kinase for an unidentified ligand. 
EMBO (Fur. Mol. Biol. Organ.) J.  6:3341. 
47.  Coussens, L.,  C.  van Beveren, D.  Smith,  E.  Chen,  R.L. 
Mitchell, C.M. Isacke, I.M. Verma, and A. Ulrich. 1986. Struc- 
tural alteration of  viral homologue of  receptor proto-oncogene 
fins at carboxyl terminus. Nature (Lond.). 320:277. 
48.  Maniatis, T., E.F. Fritsch, and J. Sambrook. 1989. Molecular 
Cloning: A Laboratory Manual. Cold Spring Harbor Labora- 
tory, Cold Spring Harbor, NY. 
49.  Feinberg, A., and 13. Vogelstein. 1984. A technique for radio- 
labeling DNA restriction endonudease  fragments to high 
specific activity. Anal. Biockem. 137:266. 
50.  Ravetch, J.V., U. Siebenlist, S. Korsmeyer,  T. Waldmann, and 
P. Leder. 1981. Structure of the human immunoglobulin m 
locus: characterization of embryonic and rearranged J and D 
genes. Cell. 27:583. 
51.  Yoshikai,  Y., D. Anatoniou, S.P. Clark, G.I. Yanagi, Y. Yoshikai, 
R. Sangster, P. van den Elsen, C. Terhorst, and T.W. Mack. 
1984. Sequence  and expression  of  transcripts of the human T-cell 
receptor B-chain genes. Nature (Lond.). 312:531. 
52.  Baer,  R., A.T. Bankier, M.D. Biggin, P.L. Deininger, p.J. Farrel, 
T.J. Gibson, G. Hatfull, G.S. Hudson, S.C. Satchwell, C. Se- 
quin, P.S. Tuffnell,  and B.G. Barrel. 1984. DNA sequence and 
expression of the B95-8 Epstein-Barr virus genome. Nature 
(Lond.). 310:207. 
53.  Lawrence,  J.B., C.A. Villnave, and K.H. Singer. 1988. Senti- 
tire, high resolution chromatin and chromosome mapping in 
situ: presence and orientation of two closely integrated copies 
of EBV in a lymphoma line. Cell. 52:51. 
54.  Stockinger, H.  1989. Cluster report:  CD68.  In  Leucocyte 
Typing IV: White Cell Differentiation Antigens. Knapp, W., 
B. D6rken, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H. Stein, 
and A.E.G.Kr. yon dem Borne, editors. 841-843. 
55.  Gadd, S.  1989. Cluster report CD13. In Leucocyte Typing 
IV: White  Cell  Differentiation  Antigens.  Knapp,  W.,  B. 
D6rken, W.K. Gilks, E.P. Rieber, R.E. Schmidt, H. Stein, 
and A.E.G.Kr. yon dem Borne, editors. 782-784. 
56.  Look, A.T., R.A. Ashmun, L.H. Shapiro, p.J. O'Connel, V. 
Gerkis, A.J. D'Apice, K, Sagawa, and S.C. Peiper. 1989. Re- 
port on the CD13 (aminopeptodase N) cluster workshop. In 
Leucocyte Typing IV: White Cell Differentiation Antigens 
Knapp, W., 13. D6rken, W.R. Gilks, E.P. Rieber, R.E. Sehmidt, 
H. Stein, and A.E.G.Kr. yon dem Borne, editors. 784-787. 
57. Jiicker, M., M. Schaadt, V. Diehl, S. Poppema, D. Jones, and 
H. Tesch. 1990. Heterogenous expression ofproto-oncogenes 
in Hodgkin's disease derived cell lines. Hematol. Oncol. 8:191. 
58.  Wu, J., J.Q. Zhu, K.K. Hart, and D.X. Zhu. 1990. The role 
of the c-fins oncogene in the regulation of HL60 cell differen- 
tiation. Oncogene (Basel), 5:873. 
59.  Cordingley, FT., A.V. Hoftbrand, H.E.  Heslop, M. Turner, 
A. Bianchi,  J.E. Reittie, A. Vyakarnam,  A. Meager, and M.K. 
Brenner. 1988. Tumor necrosis factor as an autocrine tumor 
1267  Bargou  et al. growth factor for chronic B-call malignancies. Lancet. i:969. 
60.  Cozzolino, F., A. Kubartelli, D. Aldinucci, K. Sitia, M. Torcia, 
A. Shaw, and K. DiGuglielmo. 1989. Interleukin 1 as an auto- 
crine growth factor for acute myeloid leukemia cells. Proc Natl. 
Acad. Sci. USA.  86:2369. 
61.  Kawano, M., T. Hirano, T. Matsuda, T. Taga, Y. Horii, K. 
Iwato,  H.  Asaoku,  B.  Tang, O.  Tanabe, H.  Tanaka, A. 
Kuramoto, and T. Kishimoto. 1988. Autocrine generation and 
essential requirement of BSF-2/ID6 for human multiple mye- 
lomas. Nature (Lond.). 332:83. 
62. Jricker, M., H. Abts, W. Li, K. Schindler, H. Merz, A. Grin- 
63. 
64. 
ther, C. von Kalle, M. Schaadt, T. Diamantstein, A.C. Feller, 
G.R.F. Kruger, V. Diehl, T. Blankenstein, and H. Tesch. 1991. 
Expression  of interleukin-6  and  interleukin-6-receptors  in 
Hodgkin's disease. Blood. 77:2413. 
Hsu, S.M., and X. Zhao. 1986. Expression of Interleukin-1 
in Reed-Sternberg  cells and neoplastic  cells  from the true histio- 
cytic malignancies. Am. J. Pathol. 125:221. 
Dhein, J., P.T. Daniel, B.C. Trauth, A. Oehm, P. Mrller, and 
P.H. Krammer. 1992. Induction of apoptosis by monoclonal 
antibody anti-APO-1 class switch variants  is dependent on cross- 
linking of APO-1 cell surface antigens. J. Immunol. In press. 
1268  A Novel Hodgkin Cell Line Mimicking Hodgkin's Disease in SCID Mice 